Products for Research Use Only

Hydralazine

CAT: 0804-HY-B0464ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0464ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Hydralazine is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine has antioxidant activity, as well as inhibits reactive oxygen species (ROS) release and O2·- generation with an IC50 value of 9.53 mM and 1.19 mM, respectively[1][2].
CAS Number
86-54-4
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/hydralazine.html
Purity
99.9400
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N/N=C1NN=CC2=C\1C=CC=C2
Molecular Formula
C8H8N4
Molecular Weight
160.18
Precautions
H302, H312, H332
References & Citations
[1]Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006 Feb 28;4:10.|[2]Leiro JM, et al. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol. 2004 Feb;4 (2) :163-77.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
J Pharm Anal. 2024 Jan;14 (1) :86-99.|Microchem J. 2025 Nov 24;220:116331.|Neurosci Bull. 2020 Oct;36 (10) :1158-1170.